what we do
We work globally to advocate for patient access to plasma-derived medicines, responsibly improve the availability of plasma, and advance the understanding of the plasma ecosystem.
Our association administers standards programs that help to ensure the quality and safety of plasma collection and manufacturing, as well as protect both donors and patients.
Advocacy
Advocate for access to and affordability of therapies for patients.
Engage
Engage in constructive dialogue with regulatory agencies.
Collaboration
Collaborate with patient advocacy organizations.
Standards
Administer standards and programs that ensure the quality and safety of plasma collection and manufacturing.
A global membership
PPTA members produce approximately 80% of the plasma protein therapies used in the United States today and more than 60% worldwide. Become a member and join our global network of industry leaders.
.svg)
.png)
Standards Programs
PPTA's voluntary standards program provides global leadership for the plasma protein industry's goal of continuous improvement with a focus on safety and quality from the donor to the patient. The standards program is transparent, credible, innovative, and responsive to stakeholder and industry needs.
QSEAL
People around the world depend on therapies derived from human plasma proteins to treat bleeding disorders, primary immune deficiencies, Alpha-1 antitrypsin disease and certain neurological conditions. Plasma-derived medicines are also used in emergency and surgical medicine.
Safety of plasma-derived medicines is the top priority of the plasma fractionation industry. PPTA, on behalf of its industry members, supports efforts by regulatory authorities to establish minimum requirements to ensure the safety of these products.
publications
In February 2018, Bates White Economic Consulting published a paper, Key economic and value considerations in the U.S. market for plasma protein therapies, authored by Professor Henry Grabowski of Duke University and Dr. Richard Manning of Bates White Economic Consulting. This paper analyzes the unique economic characteristics of plasma protein therapies (PPTs) and highlights their value in saving and improving patient lives.
Contact us
If you have any inquiries, get in touch with us by filling out our contact form linked below.
Members of the media are encouraged to send press inquiries to media@pptaglobal.org